Clinical Trial

Pomalidomide as an Immune-enhancing Agent for the Control of HIV

Study acronym: PEACH
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the safety and efficacy of pomalidomide in HIV-1-infected individuals on ART and to determine the impact of pomalidomide on virological control in people living with HIV during an analytical treatment interruption.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-25; most recent amendment 2026-05-01.
Status change: Recruiting → Active, Not Recruiting 2026-05-01
Status change: Not Yet Recruiting → Recruiting 2025-06-24
Trial Details
NCT Number NCT06660498
Lead Sponsor University of Aarhus
Conditions HIV-1 Infection
Enrollment 32 participants
Start Date 2025-05-13
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-07